Views & Analysis - Pharmaphorum

Trending

Latest Views & analysis

in Views and analysis
The power of blockchain in cancer care transformation
August 14, 2018 Share
X
The power of blockchain in cancer care transformation
https://pharmaphorum.com/views-and-analysis/blockchain-power-cancer-care/
in Views and analysis
Oncolytics: the dawn of a new era in cancer treatment
August 2, 2018 Share
X
Oncolytics: the dawn of a new era in cancer treatment
https://pharmaphorum.com/views-and-analysis/oncolytics-new-era-cancer-treatment/

Placing patient values at the centre of cancer treatment – a doctor’s insight

Placing patient values at the centre of cancer treatment – a doctor’s insight

Dr Michael Wong is professor of medicine at The University of Texas MD Anderson Cancer Center. He also

X

Placing patient values at the centre of cancer treatment – a doctor’s insight

https://pharmaphorum.com/views-analysis-patients/patient-values-centre-cancer-treatment/

Changing our approach to treatment decision making – an interview with Amy Berman

Changing our approach to treatment decision making – an interview with Amy Berman

Amy Berman is a senior programme officer with The John A. Hartford Foundation, a private philanthropy dedicated to

X

Changing our approach to treatment decision making – an interview with Amy Berman

https://pharmaphorum.com/views-analysis-patients/changing-approach-treatment-decision-making/

ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might

X

ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

https://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/

More Views & Analysis

ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more

ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more

Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from

X

ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more

https://pharmaphorum.com/views-analysis-oncology/asco_2018-opdivo-nektar-abbvies-leukaemia/

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance

X

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

https://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/

ASCO 2018 Preview – what to expect from this year’s conference

ASCO 2018 Preview – what to expect from this year’s conference

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the

X

ASCO 2018 Preview – what to expect from this year’s conference

https://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 months

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 months

AstraZeneca’s Bahija Jallal was named the Healthcare Businesswomen’s Association (HBA) Women of the Year for 2017 – in what turned out to a watershed year for women’s rights.

X

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 months

https://pharmaphorum.com/views-analysis-oncology/bahija-jallal-pharmas-women-of-the-year-in-a-landmark-12-months/

Improving oncology KOL engagement

Improving oncology KOL engagement

Combining technology with human insights is a powerful tool in identifying and engaging effectively with oncology experts.

X

Improving oncology KOL engagement

https://pharmaphorum.com/views-analysis-sales-marketing/improving-oncology-kol-engagement/

Kite and Sangamo come together in $3bn cancer gene editing alliance

Kite and Sangamo come together in $3bn cancer gene editing alliance

Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious

X

Kite and Sangamo come together in $3bn cancer gene editing alliance

https://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com